To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face (NCT04437745) | Clinical Trial Compass
CompletedNot Applicable
To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face
China238 participantsStarted 2020-11-25
Plain-language summary
To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female adults 18 to 65 years of age (inclusive)
* 3 (moderate) or 4 (severe) on MFVDA-SRS
* sign the written informed consent form
Exclusion Criteria:
* have streptococcal disease or bleeding disorder
* have an active or infective skin disease, scars, or tumor on mid-face
* have congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases
* have undergone facial plastic surgery, tissue grafting, or tissue augmentation with silicone, fat, or other permanent, or semi-permanent procedures/treatment
* have undergone temporary facial dermal filler within 12 months, porcine-based collagen fillers within 24 months, or neuromodulator injections, mesotherapy, or resurfacing within 6 months
* have a medical history of hypertrophic cicatrix or keloid
* have radiation therapy experience on mid-face
* have a history of anaphylaxis, multiple severe allergies, atopy, or allergy to lidocaine, hyaluronic acid products, or Streptococcal protein